[Federal Register Volume 76, Number 74 (Monday, April 18, 2011)]
[Notices]
[Pages 21753-21754]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-9269]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Noncompetitive Program Extension Supplemental Awards
AGENCY: Health Resources and Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
[[Page 21754]]
SUMMARY: The Health Resources and Services Administration (HRSA) will
be issuing non-competitive supplemental funding to the Maternal Child
and Health Bureau's (MCHB) Comprehensive Hemophilia Diagnostic and
Treatment Centers. MCHB's Division of Children with Special Health
Needs and the Genetic Services Branch are currently undergoing a
strategic planning process. This will provide feasible time for the
MCHB to align fiscal resources and programmatic goals as determined by
this strategic planning process with the least disruption to the
States, communities, and constituencies that currently receive
assistance and services from these grantees.
SUPPLEMENTARY INFORMATION: Intended Recipient of the Award:
Comprehensive Hemophilia Diagnostic and Treatment Centers--12 Regional
Centers (see table below).
Amount of the Award: 12 awards ranging from $184,846 to $595,453.
CFDA Number: 93.110.
Project Period: The period of supplemental support is from June 1,
2011, to May 31, 2012.
Authority: This activity is under the authority of Section
501(a) (2) of the Social Security Act, the Maternal and Child Health
Federal Set-Aside Program: Special Projects of Regional and National
Significance (SPRANS) (42 U.S.C. 701).
Regional Comprehensive Hemophilia Diagnostic and Treatment Centers
----------------------------------------------------------------------------------------------------------------
FY 2010
Grantee Grant No. Region Funding
Level
----------------------------------------------------------------------------------------------------------------
University of Massachusetts........... H30 MC00037-12-00............... Region 1................. $312,472
Mt. Sinai School of Medicine.......... H30 MC00019-20-00............... Region 2................. 595,453
Children's Hospital of Philadelphia... H30 MC09625-02-00............... Region 3................. 530,808
University of North Carolina.......... H30 MC05053-07-01............... Region 4-N............... 329,980
Hemophilia of Georgia................. H30 MC00011-20-00............... Region 4-S............... 228,857
Hemophilia Foundation of Michigan..... H30 MC00015-20-00............... Region 5-E............... 365,256
Great Lakes Hemophilia Foundation..... H30 MC00032-21-02............... Region 5-W............... 446,520
University of Texas HSC at Houston.... H30MC00029-20-06................ Region 6................. 455,871
Children's Mercy Hospital............. H30 MC00040-10-00............... Region 7................. 371,228
University of Colorado................ H30 MC00008-20-00............... Region 8................. 321,921
Children's Hospital of Orange County.. H30 MC00036-12-00............... Region 9................. 714,832
Oregon Health and Science University.. H30 MC00025-20-00............... Region 10................ 184,846
----------------------------------------------------------------------------------------------------------------
Justification for the Exception to Competition
Since the inception of HRSA's genetic services program, the
landscape of our health care system has changed dramatically. In
addition, our knowledge base for genetic medicine in general and blood
disorders in particular has expanded. Unfortunately, the changes in our
knowledge base and standards of care are not currently reflected in
what we measure through this program nor how they are integrated into
day to day activities that influence the health of individuals with
hemophilia, thrombophilia and von Willebrand Disease and other
congenital bleeding disorders.
To better reflect the current landscape, the MCHB is undertaking a
strategic planning process this year. At the end of the process, we
hope to have better defined measures that will reflect our new plan and
the goals for the next 10 years. This will provide us with the basis to
expand the applicant pool as well as improve the evidence base for the
utility of the National Hemophilia Program.
MCHB proposes this course of action for three reasons: (1) To
appropriately respond to the directions that will be outlined after the
strategic planning process, (2) to provide for sufficient fiscal
resource to continue programmatic activities at current levels, and (3)
to maintain MCH programmatic support with the least disruption to the
State, community, and MCH constituencies who are currently receiving
assistance and services from these grantees and the grantees
themselves. Without this approach, the programmatic changes indicated
through the strategic planning process will not be outlined nor
implemented for another 3 years when the next competitive process will
begin. Delaying the competition into mid fiscal year 2011 ensures
continuity of funding for all eligible entities, with no eligible
entity being harmed by the extension.
FOR FURTHER INFORMATION CONTACT: Sara Copeland, M.D., Maternal and
Child Health Bureau, Health Resources and Services Administration, Room
18A-19, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland
20857, Telephone (301) 443-8860, [email protected].
Dated: April 12, 2011.
Mary K. Wakefield,
Administrator.
[FR Doc. 2011-9269 Filed 4-15-11; 8:45 am]
BILLING CODE 4165-15-P